10.2. Synthesis of Other -Amino Acid Derivatives 3676 10.2.1. Synthesis of -Amino Ketones 3676 10.2.2. Synthesis of -Amino Nitriles 3679 10.2.3. Synthesis of -Amino Phosphinates 3680 10.2.4. Synthesis of -Amino Sulfonates 3681 11. Synthesis of 1,2-Amino Alcohols 3681 11.1. 1,2-Addition to R-Alkoxy Imines 3681 11.2. 1,2-Addition of R-Substituted Organometallic Reagents to N-tert-Butanesulfinyl Imines 3687 * E-mail: jellman@berkeley.edu. † These authors contributed equally to this work. Chem. Rev. 2010, 110, 3600–3740 3600

Synthesis and Applications of tert-Butanesulfinamide

Natural product and natural product derived drugs in clinical trials

The continued emergence of multi-drug-resistant bacteria is a major public health concern. The identification and development of new antibiotics, especially those with new modes of action, is imperative to help treat these infections. This review lists the 22 new antibiotics launched since 2000 and details the two first-in-class antibiotics, fidaxomicin (1) and bedaquiline (2), launched in 2011 and 2012, respectively. The development status, mode of action, spectra of activity, historical discovery and origin of the drug pharmacophore (natural product, natural product derived, synthetic or protein/mammalian peptide) of the 49 compounds and 6 β-lactamase/β-lactam combinations in active clinical development are discussed, as well as compounds that have been discontinued from clinical development since 2011. New antibacterial pharmacophore templates are also reviewed and analyzed.

/pdf/antibiotics-in-the-clinical-pipeline-in-2013-2rwtbfhz6s.pdf

Antibiotics in the clinical pipeline in 2013

Taurine (2-aminoethanesulfonic acid) is the most abundant free amino acid in humans and plays an important role in several essential biological processes such as bile acid conjugation, maintenance of calcium homeostasis, osmoregulation and membrane stabilization. Moreover, attenuation of apoptosis and its antioxidant activity seem to be crucial for the cytoprotective effects of taurine. Although these properties are not tissue specific, taurine reaches particularly high concentrations in tissues exposed to elevated levels of oxidants (e.g., inflammatory cells). It suggests that taurine may play an important role in inflammation associated with oxidative stress. Indeed, at the site of inflammation, taurine is known to react with and detoxify hypochlorous acid generated by the neutrophil myeloperoxidase (MPO)–halide system. This reaction results in the formation of less toxic taurine chloramine (TauCl). Both haloamines, TauCl and taurine bromamine (TauBr), the product of taurine reaction with hypobromous acid (HOBr), exert antimicrobial and anti-inflammatory properties. In contrast to a well-documented regulatory role of taurine and taurine haloamines (TauCl, TauBr) in acute inflammation, their role in the pathogenesis of inflammatory diseases is not clear. This review summarizes our current knowledge concerning the role of taurine, TauCl and TauBr in the pathogenesis of inflammatory diseases initiated or propagated by MPO-derived oxidants. The aim of this paper is to show links between inflammation, neutrophils, MPO, oxidative stress and taurine. We will discuss the possible contribution of taurine and taurine haloamines to the pathogenesis of inflammatory diseases, especially in the best studied example of rheumatoid arthritis.

/pdf/taurine-and-inflammatory-diseases-56ow5l0yam.pdf

Taurine and inflammatory diseases

There is growing global recognition that the continued emergence of multidrug-resistant bacteria poses a serious threat to human health. Action plans released by the World Health Organization and governments of the UK and USA in particular recognize that discovering new antibiotics, particularly those with new modes of action, is one essential element required to avert future catastrophic pandemics. This review lists the 30 antibiotics and two β-lactamase/β-lactam combinations first launched since 2000, and analyzes in depth seven new antibiotics and two new β-lactam/β-lactamase inhibitor combinations launched since 2013. The development status, mode of action, spectra of activity and genesis (natural product, natural product-derived, synthetic or protein/mammalian peptide) of the 37 compounds and six β-lactamase/β-lactam combinations being evaluated in clinical trials between 2013 and 2015 are discussed. Compounds discontinued from clinical development since 2013 and new antibacterial pharmacophores are also reviewed.

Antibiotics in the clinical pipeline at the end of 2015

Quaternary ammonium N,N-dichloroamines as topical, antimicrobial agents

N,N-Dichloroaminosulfonic acids as novel topical antimicrobial agents.

Stieglitz rearrangement of N,N-dichloro-β,β-disubstituted taurines under mild aqueous conditions

Novel N-chloroheterocyclic antimicrobials

The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds.

Timothy P. Shiau

Papers

Quaternary ammonium N,N-dichloroamines as topical, antimicrobial agents

N,N-Dichloroaminosulfonic acids as novel topical antimicrobial agents.

Stieglitz rearrangement of N,N-dichloro-β,β-disubstituted taurines under mild aqueous conditions

Novel N-chloroheterocyclic antimicrobials

N-halogenated amino compounds and derivatives